Expression analysis and clinical significance of CXCL16/CXCR6 in patients with bladder cancer

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 229-235

  Lee, Jun Taik ^a   Lee, Sang Don ^b   Lee, Jeong Zoo ^b   Chung, Moon Kee ^b   Ha, Hong Koo ^b  

^a Busan Saint Mary's Hospital   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

Bladder; Bladder cancer; Chemokines; Prognosis

Indexed keywords

CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE; MESSENGER RNA;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; CYSTECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84869049670     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.976     Document Type: Article

References (31)

1. Latini DM, Lerner SP, Wade SW, Lee DW and Quale DZ: Bladder cancer detection, treatment and outcomes: Opportunities and challenges. Urology 75: 334-339, 2009.
2. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19: 666-675, 2001.
3. Nishizawa K, Nishiyama H, Oishi S, et al: Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4. Int J Cancer 127: 1180-1187, 2010.
4. Eisenhardt A, Frey U, Tack M, Rosskopf D, Lummen G, Rubben H and Siffert W: Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol 47: 111-117, 2005.
5. Wang J, Lu Y, Koch AE, Zhang J and Taichman RS: CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res 68: 10367-10376, 2008.
6. Koizumi K, Hojo S, Akashi T, Yasumoto K and Saiki I: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 98: 1652-1658, 2007.
7. Hojo S, Koizumi K, Tsuneyama K, et al: High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 67: 4725-4731, 2007.
8. Ludwig A, Schulte A, Schnack C, et al: Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J Neurochem 93: 1293-1303, 2005.
9. Scholz F, Schulte A, Adamski F, et al: Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin. J Invest Dermatol 127: 1444-1455, 2007.
10. Tabata S, Kadowaki N, Kitawaki T, et al: Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells. J Leukoc Biol 77: 777-786, 2005.
11. Retz MM, Sidhu SS, Blaveri E, et al: CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer 114: 182-189, 2005.
12. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase iii intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15: 2564-2569, 1997.
13. Lehmann J, Retz M and Stockle M: Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. Crit Rev Oncol Hematol 47: 171-179, 2003.
14. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
15. Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet 357: 539-545, 2001.
16. de Visser KE, Eichten A and Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37, 2006.
17. Ha HK, Lee W, Park HJ, Lee SD, Lee JZ and Chung MK: Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer. Mol Med Report 4: 419-424, 2011.
18. Luster AD: Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338: 436-445, 1998.
19. Struyf S, Proost P and Van Damme J: Regulation of the immune response by the interaction of chemokines and proteases. Adv Immunol 81: 1-44, 2003.
20. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14: 171-179, 2004.
21. Sun YX, Wang J, Shelburne CE, et al: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89: 462-473, 2003.
22. Hu W, Zhen X, Xiong B, Wang B, Zhang W and Zhou W: CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci 99: 1362-1369, 2008.
23. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ and Krek W: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425: 307-311, 2003.
24. Lu Y, Wang J, Xu Y, et al: CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res 6: 546-554, 2008.
25. Darash-Yahana M, Gillespie JW, Hewitt SM, et al: The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One 4: e6695, 2009.
26. Deng L, Chen N, Li Y, Zheng H and Lei Q: CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Biochim Biophys Acta 1806: 42-49, 2010.
27. Belperio JA, Keane MP, Arenberg DA, et al: CXC chemokines in angiogenesis. J Leukoc Biol 68: 1-8, 2000.
28. Gaida MM, Gunther F, Wagner C, et al: Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections. Clin Exp Immunol 154: 216-223, 2008.
29. Held-Feindt J, Rehmke B, Mentlein R, et al: Overexpression of CXCL16 and its receptor CXCR6/bonzo promotes growth of human schwannomas. Glia 56: 764-774, 2008.
30. Gutwein P, Schramme A, Sinke N, et al: Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer 45: 478-489, 2009.
31. Ou DL, Chen CL, Lin SB, Hsu CH and Lin LI: Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy. J Pathol 210: 363-373, 2006.